Ekkehard Mössner

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Tilman Schlothauer, Sylvia Herter, Claudia Ferrara et al. · Protein Engineering Design and Selection · 2016 · 419 citations · Full text

Pharmacy, Immunology, Molecular Biology +17

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

Christian Klein, Alfred Lammens, Wolfgang Schäfer et al. · mAbs · 2013 · 386 citations · Full text

Pharmacy, Immunology, Oncology +17

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Christina Claus, Claudia Ferrara, Wei Xu et al. · Science Translational Medicine · 2019 · 266 citations · Full text

Medicine, Immunology, Oncology +17

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Gerhard Niederfellner, Alfred Lammens, Olaf Mundigl et al. · Blood · 2011 · 231 citations · Full text

Life Sciences, Immunology, Molecular Biology +13